[ad_1]
Coronavirus vaccines will be made available to more U.S. children by regulators on Monday to open the Pfizer-BioNTech jab to 12-year-olds, creating a race to protect students before they return to class this year.
The shootings could begin as early as Thursday, after a federal vaccination advisory board issued recommendations for the use of a two-dose vaccine for 12- to 15-year-olds. The announcement is expected on Wednesday.
Most COVID-19 vaccines worldwide are licensed for adults. The Pfizer vaccine is being used in several countries for teens under the age of 16, and was recently the first in Canada to spread the use of 12 and over.
Parents, school administrators and other public health officials are eagerly awaiting the shot to make more shots available to children.
U.S. President Joe Biden has issued a statement stating that the permit is “a promising future in the fight against the virus.”
“If you’re a parent who wants to protect your child or a teenager interested in getting vaccinated, today’s decision is closer to that goal,” she said.
Most children with COVID-19 develop only mild symptoms or no symptoms at all. However, children are not at risk of becoming seriously ill, and they can still spread the virus. There have been appearances at sporting events and other activities for children between the ages of 12 and 15.
Dr. William Gruber, a senior vaccination scientist at Pfizer, said the vaccine permit for young teens would help the U.S. expand its immune population and protect an age group that has not been completely saved from serious illness.
“I get to know pediatricians and people in the community about what kind of god it will be for sports activities, theater clubs, and other types of teens that we want to participate in in a natural way,” Gruber said.
“COVID-19 is a common moment in our ability to fight the pandemic.”
Inclusion of children of all ages it will be critical to return to normalcy.
It was declared by the U.S. Food and Drug Administration (FDA) The Pfizer vaccine is safe and provides great support to young people based on trials of more than 2,000 volunteers between the ages of 12 and 15.
WATCH LIVE at 7pm ET: Enter with the acting FDA commissioner @DrWoodcockFDA and @FDACBER Director Peter Marks while discussing Pfizer-BioNTech # COVID-19 vaccine for use in adolescents aged 12-15 years. https://t.co/PDF95M3LX7
– US FDA (@US_FDA) May 10, 2021
The study did not find any cases of COVID-19 among fully vaccinated adolescents among children given false comparisons at 18 years of age. More interesting researchers found that children developed higher levels of antibodies to the virus than early studies measured in young adults.
Younger adolescents received the same dose of the adult vaccine and had the same side effects, especially arm pain and flu-like fever, chills, or pain indicating a renewed system of pain, especially after the second dose.
Pfizer’s tests on teens “meet our stringent standards,” said FDA vaccine chief Peter Marks.
“Having an authorized vaccine for younger populations is a critical step in continuing to reduce the enormous public health burden caused by the COVID-19 pandemic,” Marks said.
Pfizer and its German partner BioNTech recently applied for a similar permit in the European Union to continue with other countries.
The latest news is welcome for younger families who are struggling to decide what activities they can recover from when younger family members continue to be vaccinated.
“I can’t feel completely comfortable because my boys don’t get vaccinated,” said Carrie Vittitoe, a substitute Kentucky teacher and freelance writer in Louisville who is fully integrated as her husband and 17-year-old daughter.
The FDA’s decision means his 13-year-old son could soon be a candidate, leaving only an 11-year-old son who would have been unvaccinated.
Pfizer is not the only company that wants to lower the vaccine age limit.
Moderna Inc. recently said that the first results of a study of young people between the ages of 12 and 17 have strong protection and have no serious side effects. Another U.S. company, Novavax, has the COVID-19 vaccine in its late-stage development and also began research with young people between the ages of 12 and 17.
Below is a look at whether the vaccine works for even the youngest. Both Pfizer and yes Modern They began their studies in the United States in children aged six months to 11 years.
These studies examine whether children, preschoolers, and primary school children will need different doses than adolescents and adults. Pfizer expects the first results from September.
Outside the US, AstraZeneca is studying its vaccine among young people aged 6 to 17 in the UK. And in China, Sinovac recently announced that it has submitted preliminary data to Chinese regulators that its vaccine is safe for children up to three years old.
[ad_2]
Source link
